Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

This Executive Order seeks to align U.S. prescription drug prices with those in comparably developed countries by implementing a “most-favored-nation” pricing strategy. It directs the Secretary of Health and Human Services to communicate price targets to pharmaceutical manufacturers within 30 days and to facilitate direct-to-consumer programs offering drugs at the most-favored-nation price. If significant progress is not made, the order authorizes additional actions, including proposed rulemaking, importation certifications, antitrust enforcement, export controls, and potential FDA regulatory reviews. The order also calls on the Department of Commerce and USTR to address international pricing practices that contribute to disproportionately high drug costs for American consumers.

• HHS
• DOC
• USTR

30 days.

Communicate most-favored-nation price targets to pharmaceutical manufacturers — within 30 days

No known legal challenges.